London startup raises $60M for degraders aimed at Alzheimer’s protein tau
Oyster Therapeutics has raised $60 million to develop pills that destroy pathogenic forms of tau, a brain protein implicated in Alzheimer’s disease. The Series A-2 funding was led by life-science venture capital fund 4BIO Capital ...
Two novel protein structures linked to Alzheimer's disease have been identified by researchers at Karolinska Institutet and their collaborators. The study, published in Nature Communications, reveals that amyloid-beta, a protein associated with the development of Alzheimer's, can form two previously unknown toxic intermediates. These structures, which form before plaques develop, can damage nerve cells.
However, a protein previously discovered by the research team, BRICHOS, can counteract the formation of these harmful amyloid-beta clusters. In mouse models, treatment with BRICHOS reduced the levels of these toxic forms, plaque formation, and brain inflammation, while improving cognitive test performance. The findings suggest a potential new treatment approach for Alzheimer's disease, offering an alternative to current antibody treatments which have limited effects and side effects.
Further research is needed to fully understand the role of these newly identified amyloid-beta forms in the progression of Alzheimer's, and to develop BRICHOS as a potential therapeutic agent.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Two newly identified protein forms may play a role in Alzheimer's medicalxpress.com
